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ABSTRACT 
BACKGROUND: 
Meningiomas constitute about 13-26% of primary intracranial tumours. 
Although most of the meningiomas are benign grade I tumours,they show a 
recurrence rate of about 30% . Detection of this morphologically  benign   and 
biologically aggressive   meningiomas cannot be made by routine histology 
alone. Thus in the present study Progesterone receptor, Estrogen receptor and 
Ki67 markers were used as an adjuvant approach in the identification of  these 
biologically aggressive meningiomas. 
OBJECTIVE: 
To assess the Estrogen receptor ,progesterone receptor and Ki67 expression and 
to compare and to correlate them demographically, histologically and 
immunohistochemically. 
MATERIAL AND METHODS: 
This is a cross sectional study conducted for a period of one year (July 2013-
july 2014) in the Department of Pathology,Coimbatore Medical College 
,Coimbatore. Thirty cases of meningioma were asssesed 
immunohistochemically and correlated with various clinico –pathological 
parameters. 
 
RESULTS: 
Thirty cases of meningioma were included in the study all of which were grade 
I tumours. Mean age of all cases were 45 .7 +/- 13.1 years. Females 
outnumbered males with F: M ratio of   2.7:1. Progesterone receptor positivity  
seen  in about 19 out of 30 cases(63.3%), with none of the cases showing 
estrogen receptor immunoreactivity. Also PR immunoreactivity was higher in 
females(68%). Age,location of tumor and subtypes has no correlation with 
PR.Recurrence  was noted in 7 out of 30 cases .The recurrence rate was found to 
be higher in males(25%). Progesterone expression was higher in Non recurrent 
tumours (78%). In recurrent tumours, PR expression was decreased(14%) but in 
contrast  Ki67 expression was 100% .  There is an inverse relationship  between  
Ki67  and Progesterone receptor expression. Age, Location of tumour and the 
meningioma subtypes had no role in predicting the recurrence. 
CONCLUSION: 
Although meningiomas  express progesterone receptor, it is independant of  
Estrogen receptor, unlike the other hormone dependant tumours like breast and 
uterus(58).Expression of Progesterone receptor  is associated with lesser 
recurrence and better prognosis.. Progesterone receptor can be used along with 
other histological parameters for prognostication of meningiomas(59,60) 
Thus , in  the grading of meningiomas ,histopathological examination alone is 
not sufficient, ancillary tests with Progesterone receptor and proliferative 
marker should be included for prognostication of meningiomas. 
Key words: Meningioma, Progesterone receptor,Ki67 , immunohistochemical 
study. 
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INTRODUCTION 
 
 Meningioma is the commonest primary intracranial neoplasm 
constituting about 25-30% worldwide  and the frequency of its occurance 
has increased in recent days especially in female population(1).  However 
the exact etiology is till vague and multiple etiological factors has been 
postulated. Recent studies has shown that meningiomas express sex 
hormone receptors especially the Estrogen and Progesterone receptors 
which is a promising lead into the etiology, prevention and management 
of intracranial meningiomas. 
     Meningioma is thought to arise from meningeal cap cells which are 
not normally thought to be a target tissue for estrogen ,progesterone 
action. However numerous studies have showed the role of progesterone 
in growth and development of meningiomas. 
Higher incidence of meningiomas is seen in the women of 
reproductive age group, when there is maximal gonadal activity. Also 
there is clinical and radiological evidence of rapid tumour progression 
during pregnancy and luteal phase of menstrual cycle. 
Numerous studies have shown Progesterone expression and to a 
lesser extent estrogen receptor expression in most of the meningioma 
specimens. Predicting the behaviour of meningiomas with routine 

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histopathological examination alone is not sufficient. Various literature 
have shown that the  expression of progesterone receptor is associated 
with lesser recurrence and better prognosis of patients. Thus the study is  
aimed at assessing the expression of hormonal receptors (ER, PR) along 
with proliferation index in the meningiomas specimens and to correlate 
them  histomorphologically. 
                                                    
 
 
 
 
 
 
 
 
 
 
 



 
 
AIMS & OBJECTIVES 
1. To analyse and compare the Estrogen receptor, progesterone 
receptor and Ki67 expression using immunohistochemical method. 
2. To assess the histological grades and subtypes of meningiomas 
using Hematoxylin and Eosin sections. 
3. To correlate ER, PR and Ki67 expression with histological grades 
and subtypes  
4. To correlate ER, PR and Ki67 expression  in non recurrent and 
recurrent tumours. 
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REVIEW OF LITERATURE 
HISTORY AND NOMENCLATURE: 
 
The earliest evidence of meningioma was found in a   365,000years 
old  skull, in Germany .An autopsy done by Felixplater of the University 
of Basel was the first literature evidence of meningioma was in 1600. The 
characteristic fungal like growth of meningioma was described in detail  
by Louis in 1774.The first successful removal of meningioma dates back 
to 16 century. 
Until early twentieth century  these tumours were referred by 
various names which include Endotheliomas, Psammomas, 
Meningioexoepitheliomas and Arachanoid fibroblastomas.The term 
“meningioma” was coined by HARVEY CUSHING in 1922 for a set of 
tumours that occurred throughout neuraxis (2). In 1938 Drs.Harvey 
cushing and Louise were the first to publish a monograph 313 
meningiomas.Later in 1970 Charles Oberling  subtyped  meningiomas  
based on the cell structure. Another major monograph was published by 
John kepes after observing some 1300 cases. In 1979 World health 
organization(WHO) classified meningioma into seven subtypes then it 
was upgraded in 2000 into nine variants belonging to grade 1 ,three 
variants belonging each to grade 2 and grade 3. 

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ANATOMY AND HISTOLOGY: 
The brain and spinal cord is covered by the meninges which is a 
tripartite coverings consisting of outer dura, middle arachanoid, inner pia 
mater. 
The normal dura mater is a tough ,thick membrane hence it was 
previously referred to as “Pachymenix” which means “Thick 
meninges”.The literal meaning of the word  Dura mater  is “Tough 
mother”.It  consists of two layers,the outer layer is affixed to overlying 
periosteum and the inner layer covers the brain matter.In the spinal region 
the dura mater is not attached to the spine creating extradural 
space.Histologically dura is a dense collagenous structure with cells 
having a fibroblastic appearance.Most of the meningiomas are attached to 
the overlying dura.(3) 
Arachanoid cap cells: 
The middle arachanoid layer is a “spider like” 
membrane.Histologically it consists of 2 types of cells.The outer cells are 
spindle shaped as seen in fibrous meningiomas and the inner cells are 
polygonal in shape.Interspersed among these are the meningothelial cell 
nests which are round to oval cells with slightly oval nucleus showing 

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delicate chromatin and inconspicuous nuclei. These aggregate  into 
grossly visible mass “arachanoid granulations”. 
The arachanoid granulations are clustered at locations where dural 
venous drainage is prominent that is along superior saggital sinus,major 
venous sinuses at skull base. These sites closely mimics meningioma 
distribution providing  a clue that meningioma arises from arachanoid cap 
cells. These cells can also be found in variety of unusual locations like  
orbital,head and neck region and in the intraventricular region.This 
unusual location may be due to embryological misadventures. 
Functions of Arachanoid cap cells: 
a)Wraping  around  each other , the  surface of CNS,proximal portions of 
CNS,blood CSF barriers. 
b)Helps to maintain CSF homeostasis by protein seretion 
c)Providing trophic support for migrating neuroglial cells 
d)Macrophage like function rarely. 
Pia mater is the inner most and inconscpicous cell layer of 
meninges with tight attachment to the brain matter.It follows the contour 
of the brain and divides into Virchow-robins spaces. Disruption of the 
pia- glial barrier is histologically ominous sign when evaluating 
meningiomas.   
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EPIDEMIOLOGY: 
Meningiomas are the commonest intracranial neoplasm 
constituting about 25-30% of central nervous system neoplasms 
worldwide. Annual incidence rate is about six to thirteen percent per 
100,000 persons. At autopsy meningiomas is an incidental finding in 
about 1.4% cases.Sporadic meningiomas constitute around 10% of 
cases.According to current studies it has been shown that atypical 
constitute around 20 %. Those cases belonging to malignant/anaplastic 
meningiomas constitute only upto 2 .2 %. The increased incidence of 
meningiomas is attributed to the increased diagnostic modalities and also 
probably the increased exogenous risk factors.  
SITE PREDILECTION: 
Meningiomas are typical for their location, being attached to inner 
surface of the duramater of meningiomas which possibly excludes other 
intracranial neoplasms. Majority of meningiomas arise within intracranial 
and intraverterbral cavities.(4)  
1)Parasaggital/falx cerebri 
2)cerebral convexities. 
Among the intracranial tumours 40% arise over cerebral 
convexities closely attached to falx cerebri..Majority of the parasaggital 
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meningiomas occur in the middle one third. Falcine tumours may occur 
bilaterally with mirror image lesions on either side  Other common sites 
include 
3)sphenoid ridge 
4)suprasellar 
5) olfactory grooves 
6)posterior fossa 
7)middle fossa 
8)Tentoril 
9)Petrous ridges 
  Optic nerve sheath involvement is rare in meningiomas. Intra 
ventricular meningiomas arise from the rest of  meningothelial tissue that 
is carried along with choroid plexus during embryogenesis.It occur most 
commonly in the lateral ventricles,more frequently left lateral ventricle 
than the right lateral ventricle ,the reason for which is not known.also 
intraventricular meningiomas are more common in children. 
Spinal meningiomas tend to be more common in the thoracic 
region occupying the anterior and more lateral location of spine. 
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Multiplicity of spinal meningiomas is rare but can occur in 
neurofibromatosis 2 patients.  
  Atypical or malignant variants are more common on the lateral 
convexities and falx cerebri. Metastatic deposits of malignant 
meningioma occur in the lung,lymph node,liver,bones,pleura. 
AGE & SEX PREDILECTION: 
The incidence of meningiomas are more common in middle aged 
and elderly patients.Incidence increases with age with a median age of 64 
years at the time of diagnosis. The incidence of meningiomas are less in 
children ie only 1.9% of all intracranial neoplasms in children are 
meningiomas. After the age of 35 meningiomas are the most common 
intracranial tumour. Meningioma occurring in hereditary syndromes like 
Neurofibromatosis type 2 typically occur in younger patients. The age 
standardized incidence rate of meningioma was 5.5per one lakh for 
females and 1.6 per one lakh for males.( Finnish cancer registry 2001) 
Of the all intracranial neoplasms 38% in females and 20% in males 
are meningiomas  with female to male ratio 2:1.(5). In women the most 
common spinal tumour is meningioma. The female to male ratio in spinal 
meningiomas is 3-4: 1.However higher grade of meningiomas (atypical 
and anaplastic)are more common in male.Also childhood meningiomas 
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tend to be more common in males.Meningiomas in hereditary syndromes 
occurs equally in male and female.(6) 
 According to The Central Brain Tumour Registry of the United 
States 2011 statistical report the women to men sex ratio was 2.2:1. The 
actual incidence rates of meningiomas is higher than the above studies 
since surgical treatment and diagnosis are not done for all cases of 
meningiomas.(7) This is favoured by an Autopsy study by Krampla et al., 
2004 which showed an prevalence of 2.8% of subclinical meningiomas in 
females. (8) 
Risk factors : 
 There are multiple risk factors that have been postulated to increase 
the incidence of meningiomas. These are described below 
1. Radiation exposure: Many studies has shown an increased risk of 
meningiomas following radiation exposure.These cases are 
associated with multifocality and aggressiveness. 
Average interval of time for tumour development following 
low,medium and high dose radiation is 35 years,25-27 years,19-23 
years.  
Meningiomas tend to occur following low dose irradiation which 
constitute 800 rads for treating tinea capitis. 
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High dose of radiation which is 2000rads for treating primary 
central nervous system tumours results in multifocal.more 
aggressive,atypical,anaplastic meningiomas. 
Radiation induced meningeal tumours tend to occur in younger age 
with high proliferative index.   
 In a study in Israel by Ron et al., 1988 the relative risk of 
developing meningiomas was increased in a age matched cohort 
study of 10,834 children treated with low dose radiation therapy for 
Tinea Capitis compared to a control group who didn’t undergo 
irradiation.(9) 
 In a study by  Al-Mefty et al., 2004  the incidence of secondary 
meningiomas is increased following high dose radiation therapy to 
the head and neck region in children for other tumours. (10) 
In a study conducted by Gallowy et al., 2011 the children who had 
radiation treatment need long term follow up since the risk of 
incidence of meningiomas increases after ten years of radiation 
treatment. (11) A study by Strojan et al 2000,The radiation induced 
meningiomas occur at an younger age, are often multiple, more 
often anaplastic and have high tendency for recurrence.(12) 
2. Occupational risk factors:  The risk of meningioma is increased 
among men exposed to lead. Navas-Acien et al showed in his study 
that,Women who have occupational exposure to herbicides have 
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increased risk of meningiomas compared to women who were not 
exposed. (13) 
3. Medical risk factors:  Women with a previous breast cancer have 
an increased risk of meningioma occurance in later life compared 
to women without previous breast cancer.  
Custer et al., 2002 noticed increased risk for breast cancer in 
female meningioma patients. Uterine fibroids and endometriosis 
which are sex hormone related conditions are more common in 
females   with meningiomas than controls.(14)  
4. Genetic risk factors: Meningioma occurs in 50% of patients with 
Neurofibromatosis 2 which is an Autosomal dominant disorder. (15) 
In Neurofibromatosis 2 patients the meningiomas occur at younger 
age, are often multiple compared to sporadic meningiomas which 
occur at older age and rarely multiple. The meningiomas occurring 
in NF 2 patients are more often Fibroblastic subtype and also more 
aggressive than sporadic meningiomas. The risk of meningiomas is 
higher in persons with a family history of meningioma. 
5. Hormonal therapy: In 2003 Jhawar et al found an increased risk of 
meningiomas in women who were receiving Menopausal 
Hormonal Therapy for the first time which increased the attention 
to the role of sex hormones in meningiomas.(16) 
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Similarly two other studies by Wigertz et al. in 2006 and Blitsteyn 
et al., in 2008 confirmed the above findings which provided a new 
angle into the incidence of meningiomas.(17),(18). 
     A study called The Million Women Study, a prospective which 
included 11,47,894 post menopausal women with a mean follow up 
of 5.3 years a total of 311 meningiomas were observed. This study 
showed increased relative risk of meningiomas of 1.34 among 
current users and 1.29 among past users. Among the current users 
the relative risk was increased to 1.44 for those who were using 
estrogen Only Therapy. Results on studies correlating meningioma 
incidence with Oral Contraceptives were inconclusive. 
6. Head Injury: According to Barnett et al 1986 the chronic 
inflammation and granuloma formation following head injury may 
cause irritation of nearby meninges which leads to formation of 
tumour. But the association of meningioma post head injury is 
inconclusive according to many studies.(19) 
CLINICAL FEATURES: 
Symptoms and signs depends on primary location of tumour. These 
slow growing tumours usually produce symptoms by compressing the 
adjacent structures.they may grow to a considerable extent before 
producing clinical symptoms.This is usually seen with Olfactory groove 
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meningiomas.These lesions produce central scotoma,ipsilateral optic 
atrophy,Ipsilateral insomnia,with contralateral pappiloedema. Tumours 
located on the upper falx presents motor and sensory disturbances of 
lower extremity.More laterally located lesions produce hand  and neck 
signs and symptoms.Base of skull tumours produce a more non-localising 
symptom like headache,but sometimes they may entrap the cranial nerve  
and produce the symptoms. Sphenoid ridge meningiomas present with 
unilateral visual loss with painless exophthalmos. Tuberculum sellae 
masses present with bilateral hemianopsia,and optic atrophy. 
Cerebellopontine angle meningioma present with hearing loss and 
cerebellar signs. Foramen magnum tumours present with spastic paresis 
and sensory loss of upper extremity.Underlying tumoral edema can by 
itself provokr neurological signs and symptoms.Rarely they may invade 
into overlying skull and scalp producing scalp nodules. 
• New neurological deficit 
• Seizure 
• Symptoms of raised intracranial pressure 
• Proptosis 
• Cavernous sinus syndrome 
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DIAGNOSIS OF MENINGIOMA: 
Magnetic Resonance Imaging (MRI) is the investigation of choice 
for the diagnosis of meningiomas eventhough Computerised Tomography 
(CT) can also be used and readily available. In some cases of 
meningiomas with adjacent bony involvement and calcifications CT is 
more useful than MRI.  
On imaging meningiomas are seen as extra-axial masses which are 
round or elongated which often shows dural attachment. Meningiomas 
more commonly show homogenous enhancement after administration of 
contrast material and sometimes can show heterogenous enhancement. 
On Magnetic resonance imaging ,meningiomas appear as isodense, 
dural based contrast enhancing masses.calcification is seen best on 
Computed tomography.charecteristic feature is the “dural tail” which are 
either dural extension of tumour or a rim of fibrovascular(reactive) tissue. 
Peritumoral edema is seen prominently in atypical or anaplastic 
meningioma. 
Zee et al in his study showed that,2-10% of meningiomas show 
cystic in nature and may cause difficulty in diagnosis. (20) 24% of 
pediatric meningiomas show cysts which is less common in adult 
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meningiomas.(21) Hyperostosis of skull adjacent to meningioma seen in 
MRI represents direct invasion of meningioma into the skull bone. 
 There is no specific feature on imaging studies in routine CT & 
MRI which differentiates benign meningiomas from malignant 
meningiomas. Aggressive histological features in meningiomas can be 
predicted using Diffussion and Perfusion MRI.  
According to Nagar et al., 2008 more aggressive tumours are 
associated with less water diffusivity shown in diffusion MRI and are 
more prone for recurrence. The vascular supply of meningiomas can be 
seen in perfusion MRI. It is said that the vascular supply of meningiomas 
differs between benign and malignant meningiomas i.e., the main blood 
supply of benign meningiomas is via the dural branches of external 
carotid artery wheras high grade meningiomas receive blood supply 
mainly from the Pial-Cortical branches. Hence in benign meningiomas 
which receives blood supply from the dural branches lack blood brain 
barrier and Gadolinium can permeate into the tumour tissue and shows 
typical curve whereas in high grade meningiomas which receives blood 
supply from the pial branches have blood brain barrier shows return of 
intensity to baseline levels on perfusion scans. 
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NATURAL HISTORY OF MENINGIOMAS: 
 Many cases of meningiomas are diagnosed incidentally due to the 
widespread use of CT and MRI’s. This may also be the reason for 
increase in incidence of meningiomas of late. Majority of patients with 
meningiomas which was diagnosed incidentally are asymptomatic. Most 
of these cases show only minimal growth and can be followed up with 
serial imaging with treatment to be initiated if there is progress of growth. 
A study by Nakamura et al., 2003, Patients less than 60 years of 
age seem to have increased growth potential compared to patients older 
than 60 years.The initial tumour size at the time of diagnosis  is not a 
predictive factor for growth of meningioma. In meningiomas showing 
calcification in tumour tissue is associated with lack of growth.(22) 
  A study by Yano et al., 2006 showed that approximately about 
1/3rd of meningiomas progress based on the natural history of these 
tumours. Meningiomas have potential to progress to higher grades i.e., 
benign to atypical or malignant.(23) Approximately 1/3rd of recurrent 
meningiomas are transformed to higher grade.(10) 
 
 
 
GROSS: 
Most of the meningiomas are  well demarcated masses with a 
broad based dural attachment. They are gray white to tan, rubbery to firm 
consistency with a trabeculated or whorled cut 
leiomyoma.sometimes they have a gritty aparance due to large number of 
psammoma bodies.Adjacent parenchyma is compressed. meningiomas 
along sphenoid wing grow as flat,carpet like masses termed “en plaque” 
variant. Invasion of the dura or
gives rise to characteristic hyperostosis.They may invade the infiltrate the 
overlying skin with orbital extension.atypical and anaplastic 
meningiomas are larger with areas of necrosis.
 
	
surface similar to 
 dural sinuses is common. skull invasion 
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CLASSIFICATION OF MENINGEAL TUMOURS: 
According to WHO(2007) the following tumours are included in 
meningeal tumours(24)    
• Mesenchymal non-meningothelial tumours 
a) Lipoma 8850/0 
b) Liposarcoma 8850/3 
c) Angiolipoma 8861/0 
d) Hibernoma 8880/0 
e) Solitary fibrous tumour 8815/0 
f) Fibrosarcoma 8810/3 
g) Malignant fibrous histiocytoma (MFH) 8830/3 
h) Leiomyoma 8890/0 
i) Leiomyosarcoma 8890/3 
j) Rhabdomyoma 8900/0 
k) Rhabdomyosarcoma 8900/3 
l) Chondroma 9220/0 
m) Osteoma 9180/0 
n) Osteochondroma 9210/0 
o) Chondrosarcoma 9220/3 
p) Osteosarcoma 9180/3 
q) Haemangioma 9120/0 
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r) Epithelioid haemangioendothelioma 9133/1 
s) Angiosarcoma 9120/3 
t) Kaposi sarcoma 9140/3 
u) Ewing sarcoma-peripheral primitive neuroectodermal 
tumour 9364/3 
• Hemangiopericytoma 
a) Haemangiopericytoma 9150/1 
b) Anaplastic haemangiopericytoma 9150/3 
• Melanocytic lesions 
• Hemangioblastoma 
Haemangioblastoma WHO Grade I    9161/1 
  The WHO classification of the tumours of the CNS 2007 classifies 
meningioma into three grades and thirteen histological subtypes. The 
three grades are 
1. Grade I – Benign 
2. Grade II – Atypical 
3. Grade III – Anaplastic or Malignant 
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GRADE I  MENINGIOMAS: 
Meningiomas are most commonly benign or Grade I. Even though 
there are various histological subtypes for benign meningiomas the 
treatment and prognosis doesn’t differ much in them.  
The subtypes that are more common are  
• Meningothelial Meningioma     9531/0 
• Transistional meningioma         9537/0 
• Fibrous Meningioma                9532/0 
Followed by other common subtypes such as 
• Psammomatous Meningioma 9533/0 
• Angiomatous  Meningioma   9534/0 
• Microcystic Meningioma      9530/0 
• Secretory Meningioma  9530/0 
• Lymphoplasmocyte rich Meningioma      9530/0 
• Metaplastic meningiomas Meningioma      9530/0 
CYTOLOGY: 
Intraoperative smear preparation is helpful to demonstrate the 
cytological features of meningioma.The cells are  round  to oval.Nuclear 
feature are distinctive.They are slightly oval nuclei with a delicate 
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euchromatin with inconscpicous nuclei.The most characteristic feature is 
the presence of intranuclear inclusions.These inclusions are also called as 
“orphan annie eye”inclusion.  Two forms of nuclear inclusions are seen. 
1)sharply defined pinkish or eosinophilic cytoplasmic inclusion 
2)Diffuse washing out of nuclei . 
Other characteristic feature that points to a diagnosis of 
meningioma are whorls and psammoma bodies.cellular whorls are 
colletions of cells arranged in concentric lamellated fashion.cells in the 
centre of the whorls are more polygonal whereas cells in the outside of 
whorls are elongated .These whorls are tight to loosely wound clusters.on 
intraoperative smear preparation these tight cellular whorls are clues to 
the diagnosis of meningioma.however these whorls are not 
pathognomonic of meningioma as these can be seen in other tumours as 
in  schwannoma. Psammoma bodies are concentric lamellated 
calcifications .these calcification initially appear in the centre of the 
whorls.These can range from punctate tiny deposits to large 
calcifications.however these are not diagnostic of meningioma as it seen 
in tumours like schwannoma,metastatic tumours. 
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GRADE I MENINGIOMAS  (25): 
1)MENINGOTHELIAL MENINGIOMA: 
Also called as synctial meningioma.Histologically composed of 
clusters of meningeal cells which have a synctial appearance due to tight 
interdigitating cellular processes.Individual cells have round to oval 
nuclei with finely stippled chromatin eith small indistinct nucleoli.Few of 
the nucleus exhibit nuclear psudoinclusions.psammoma bodies and 
whorls are sparse often. 
Differential diagnosis: 
a)Meninioangiomatosis, 
b)Arachanoidal hyperplasia. 
c)Melanocytic neoplasm: 
They have a more prominent nucleoli,with a clearly well defined 
cytoplasmic margins.It is frequently immunoreactive for S-100 and 
HMB-45.EMA is always negative.On ultrastructural examination  it may 
contain melanosomes. 
d)Glioma: 
They have a diffuse pattern of brain infiltration,with positive 
immunoreactivity for GFAP.It is not immunoreactive for EMA. 
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2)FIBROUS/FIBROBLASTIC MENINGIOMA: 
On gross examination these lesions exhibit a rubbery ,firm 
texture.On microscopic examination they show mesenchymal 
differentiation with spindle cells arranged in storiform pattern and in wide 
fascicles in a thick collagenized matrix.The fascicles are more organized 
than in schwannoma which have more haphazard pattern.Rarely 
“amianthoid fibres” which are collagen fibres that accumulate in a stellate 
form. 
Differential diagnosis: 
a)Schwannoma: 
They show a pericellular reticulin distribution. 
b)Pilocytic astrocyoma, 
c)Fibrillary astrocytoma, 
d)Solitary fibrous tumour. 
Collagenous bundles  differentiates this from schwannoma and 
astrocytoma. 
3)TRANSITIONAL MENINGIOMA: 
They exhibit features of both synctial and fibrous 
meningioma.Prominent meningeal whorls and psammoma bodies makes 
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them easiest to diagnose with hematoxylin &eosin.vague lobular and 
fasicular arrangements are seen along with these psammoma bodies and 
tight whorls. 
Differential diagnosis: 
Pilocytic astrocytoma, 
Schwannoma 
4)PSAMMOMATOUS MENINGIOMA: 
These tumours are characteristically seen in the thoraco spinal 
region of a middle aged female. In this subtype psammoma bodies is seen 
predominantly over that of meningothelial cells. Psammoma bodies are 
lamellated calcospherules.unusually these psammoma bodies can become 
confluent with tumour meningothelial cells being difficult to find. 
occassional bone formation can be seen. 
Differential diagnosis: 
Psammomatous schwannoma, 
Metastatic adenocarcinoma with psammoma bodies. 
4)ANGIOMATOUS MENINGIOMA: 
In this variant there is large number of vascular channels which are 
small to medium sized ,thin walled or thick hyalinized walls. Nuclear 


atypia which are degenerative in nature can be moderate to marked. 
Adjacent cerebral parenchyma exhibit cerebral edema which can be out 
of proportion to the tumour size.(26) 
Differential diagnosis: 
a)Hemangioblastoma :Shows a characteristic arrangement of capillaries 
and stromal cells.EMA  and vimentin is negative.On electron microscopy 
no desmosomal junctions are seen. 
b)Vascular malformations: Arterio venous malformation shows an 
absence of menigothelial cell nests. 
c)Hemangiopericytoma 
4)MICROCYSTIC MENINGIOMA: 
As the name implies there are many microcystic spaces which 
contain eosinophilic ,pale mucinous fluid. Fluid is derived from the 
transduation of plasma across the stromal vasculature which are 
frequently hyalinized.cells exhibit cytoplasmic clearing due to 
lipid/glycogen accumulation.Numerous pleomorphic cells are seen which 
are degenerative in nature are seen.however this variant is benign in their 
behavior.It has also been referred to as “Humid meningioma”(Forme 
humide of Masson) 
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Differential diagnosis : 
 a)Low grade microcystic astrocytoma, 
b)Hemangioblastoma. 
Features like nuclear hyperchromasia,plemorphism and 
nucleomegaly suggest this differential however there is no mitotic 
activity which excludes microcystic astrocytoma. 
5)SECRETORY MENINGIOMA: 
Histologically these are composed of pseudopsammoma bodies. 
These  are epithelial cells with intracellular lumina containing 
eosinophilic PAS positive secretion which are hyaline globular 
inclusions. Mast cells are numerous. peritumoural cerebral edema is 
prominenent.  
Ultrastructuraly these spaces are microvillus lined 
spaces.Immunohistochemical evaluation shows a positivity for 
IgA,IgM.Carcinoembryonic antigen immunoreactivity is seen in these 
secretions.CEA levels rise with recurrence hence used to monitor 
patients. 
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Differential diagnosis: 
a)Metastatic carcinoma:Cells have more clearly defined margins,with 
more anaplasia and increased mitoses.Carcinomas are more commonly 
cytokeratin positive. 
6)LYMPHOPLASMACYTE –RICH: 
This is the rarest of all the variants showing extensive chronic 
inflammatory cell infiltrates composed of lymphocytes and plasma cells. 
These inflammatory cells can be so numerous that it can obscure the 
underkying meningeal tumour.Associated systemic abnormalities like 
hyperglobulinemia and refractory iron deficiency anemia is documented 
in few cases(27). 
Differential diagnosis: 
Primary hematopoietic processes 
7)METAPLASTIC MENINGIOMA: 
Meningioma composed of mesenchymal elements like 
osseous,lipomatous,cartilaginous,xanthomatous or myxoid tissue which 
can be focal or widespread. 
Differential diagnosis: 
Primary mesenchymal lesions .eg. Osteoma 
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8)SCLEROSING MENINGIOMAS: 
These tumours are frequently seen in pediatric age group. There is 
progressive  fibrous obliteration with few of the foci exhibiting 
pleomorphism, hyperchromasia. However these belong to WHO Grade 1 
tumours. (28),(29) 
GRADE II MENINGIOMA: 
The subtypes in this are as follows 
Atypical meningioma 9538/1 
Clear cell meningioma 9538/1 
Chordoid meningioma 9538/1 
ATYPICAL MENNGIOMA: 
They constitute about 4-7% of meningiomas. Increased mitotic 
activity is the characteristic feature i.e about 4 to 19 mitoses per 10 hpf. 
Brain invasion is an independent criterion of Atypical meningiomas. In 
tumours with less mitotic activity to be classified as Grade II it must have 
three or more of the following features. (30) 
1. Increased cellularity 
2. Small cells with high nucleus to cytoplasm ratio 
3. Prominent Nucleoli 
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4. Uninterrupted patternless or sheet like growth 
5. Spontaneous or geographic Necrosis 
1)Hypercellularity: 
Hypercellular regions denote areas in which there is “small cell 
formation” that is cells with increased nuclear cytoplasmic ratio  
,hyperchromatic nuclei,with scant cytoplasm. 
2)Lack of classic architectural pattern: 
Three classic patterns are seen which includes  
a)lobular in meningothelial, 
b)Fasicular in fibrous, 
c)Whorling in transitional and other forms. 
Lack of these characteristic pattern prompt us to the diagnosis of 
atypical meningioma.”Sheeting” occurs in atypical meningioma in which 
tumour cells form large sheets devoid of whorls or fascicles.one of the 
helpful feature in evaluating sheeting is evaluation of cytoplasmic 
borders.The crisp and distinct cytoplasmic borders suggest that sheeting 
is real. 
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3)Necrosis: 
Three patterns of necrosis is commonly encountered. 
1)Large , geographic areas of necrosis which can be ischaemic or 
infarctive in nature 
2)Multifocal ,small areas of necrosis with cellular debris. 
3)Single cell death 
However multifocal centrilobular form of necrosis is highly 
characteristic of atypical meningioma.Perinecrotic pseudopalisading is 
seen sometimes leading to misinterpretation as glioblastoma.Preoperative 
embolisation lead to large geographic ,infarctive type of necrosis. 
4)Mitotic activity: 
Benign meningiomas has some scattered mitotic figures but these 
are not atypical mitotic figures.  
Clear cell meningioma and Choroid meningiomas are rare subtypes 
of atypical meningiomas. Choroid meningioma resembles to chordoma 
histologically. 
2)CHORDOID MENINGIOMA: 
These are composed of cords and trabeculae of eosinophilic 
,vacuolated cells in a abundant mucoid background.they resemble 
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chordoma hisologically but can be differentiated by their meningothelial 
nuclei and whorl formation.castlemans disease is infrequently associated 
with chordoid meningioma. (31) 
Differential diagnosis: 
chordoma 
3)CLEAR CELL MENINGIOMA : 
They exhibit predilection for young adults including children and 
are most often found in the cerebellopontine and cauda equina region. 
These extracranial dural based lesion are patternless meningioma with 
polygonal cells containing water clear cytoplasm ,which are glygogen 
rich showing PAS positive ,diastase resistant reactivity. psammoma 
bodies are not  seen in this variant. Higher rates of recurrence ,frequent 
CSF seeding,increased moratality characterize this aggressive variant. (32) 
Differential diagnosis: 
Oligodendroglioma 
Central neurocytoma 
Clear cell ependymoma 
GRADE III MENINGIOMA: 
Anaplastic meningioma 9538/3 
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Rhabdoid meningioma 9538/3 
Papillary meningioma 9538/3 
1)ANAPLASTIC MENINGIOMA: 
 This constitute 1-3% of all meningiomas. It tends to occur in 
relatively younger age groups with male predominance.  
a)They have high mitotic index ie about 20 mitosis per 10 HPF or  
b)meningoepithelial differentiation is lost with appearance resembling 
sarcoma, carcinoma or melanomas.(30) 
Differential diagnosis: 
Metastatic carcinoma 
Metastatic melanoma, 
Sarcoma 
They are prone for local recurrence and distant metastasis. Some 
rare subgroups included in Grate III are rhabdoid and papillary 
meningiomas. 
2) PAPILLARY MENINGIOMA: 
These are characterized by perivascular ependymoma like 
clustering of tumour cells around the vasculature. conventional 
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meningothelial regions are almost identifiable but they exhibit increased 
cellularity,mitoses,and foci of necrosis.local invasion and brain invasion 
is noted in 75% cases,recurrence in 55% cases.and lung metastasis in 20 
% cases.(33). 
Differential diagnosis: 
Metastatic papillaryadenocarcinoma,  
Malignant melanoma,Ependymoma,Choroid plexus tumours. 
3)RHABDOID MENINGIOMA: 
These correspond to clinically aggressive grade 3 meningioma. 
Histologically composed of  sheets of rhabdoid cells which are large cells 
with abundant cytoplasm containing globose,inclusion like bodies which 
are cytoplasmic vimentin filaments  and eccentric nucleus,open 
chromatin and a prominent nucleolus. Brain invasion and increased 
mitoses is the rule.(34) 
Differential diagnosis: 
Metastatic rhabdoid tumour 
Metastatic carcinoma 
Metastatic melanoma 
Malignant glioma 
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Atypical rhabdoid/teratoid tumour 
Rhabdomyosarcoma 
Oncocytic meningiomas: 
These cells exhibit cytoplasmic fine granularity due to increased 
number of mitochondria. 
Differential diagnosis: 
Oncocytic tumours 
BRAIN INVASION AND METASTASIS: 
Most meningiomas indent the underlying brain parenchyma 
however about ¼ of cases show brain invasion. 
Gross: Attention should be paid to the presence of cerebral tissues. 
Microscopy: 
It can occur in benign,atypical,anaplastic meningioma.It denotes 
high rates of recurrence. brain invasion does not alter the grade of 
meningioma. 
Two patterns of invasion is seen: 
1) It is characterized by broad nodules of tumour invading Virchow 
robins spaces superficially with mild gliosis of  the adjacent parenchyma. 


However this pattern of involvement warrants the clinician for close 
follow up. Also this does not mean the tumour is malignant 
2) These are characterized by irregular tongue like extensions infiltrating 
the underlying cerebral parenchyma. This denotes an aggressive 
/malignant behavior of the tumour. 
Genetically these lesions exhibit ch.1p and 14q deletions 
.entrapped brain parenchyma are GFAP positive against the GFAP 
negative tumour extensions. 
 METASTASIS: 
The common sites for metastasis include lung,liver,pleura,bone. 
metastasis denotes a tumour as malignant.there is an entity known as 
“benign metastasizing “ meningioma in which a histologically benign 
meningioma is associated with a histologically benign metastasis in liver 
or lung. Excision is the treatment of  choice. Recurrences are rare. 
2)Involvement of local sites do not qualify a tumour as malignant. It 
means meningioma with involvement of overlting skin or skull does not 
mean a tumour as malignant. 
3)Invasion of dural sinuses also does not mean a tumour as malignant. 
However the extensive local spread of tumour will be difficult to resect 
and hence more prone for recurrence. 
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4)Extracranial meningiomas : 
These should not be mistaken for metastasis.These cases has no 
intracranial lesions. Sites favoured for extracranial sites include 
a.Skin 
b.Lung 
c.Nasal cavity 
d.Paranasal sinuses 
e.Oral cavity 
f.Parotid gland 
g.Ear 
h.Mediastinum 
i.Soft tissues of neck 
j.Peripheral nerves  
These extracranial meningiomas are characteristically 
meningothelial meningiomatous  type.most are benign grade 1 tumours 
which are treated with excision. 
Bony invasion through osseous canaliculi is not a sign of 
malignancy. 
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Mahmood et al in his study has laid down criteria for grading of 
meningiomas. 
• GRADING OF NUCLEAR PLEOMORPHISM: 
Grade 0-Tumour cells with uniform nuclei, dense chromatin 
and inconspicuous nucleoli. 
Grade 1-occasional tumour cells show nuclei that is 2-3 
times enlarged with irregular nuclear contours 
Grade 2-  Predominant cells with nuclei larger than 
meningothelial nuclei with pale chromatin with small or 
absent nucleoli. 
Grade 3- vesicular nuclei with single or multiple prominent 
nucleoli . 
• GRADING OF HYPERCELLULARITY: 
Grade 0 – tumor entirely composed of meningothelial 
whorls/10 hpf. Tumor cells are large with vesicular 
chromatin and abundant cytoplasm. 
Grade 1-tumour is predominantly composed of whorls with 
perivascuar areas having smaller cells and loss of pattern. 
Grade 2-predominantly composed of smaller and less 
defined whorls. 
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Grade 3-cells tightly packed with overlapping nuclei and 
scant cytoplasm. No distinct whorl formation seen. 
• GRADING OF MITOTIC FIGURES: 
Grade 0 – no mitoses/10 hpf 
Grade 1   1-2 mitoses/10hpf 
Grade 2   3-4mitoses/10hpf 
Grade 3    >=5 mitoses/10 hpf 
• GRADING OF NECROSIS: 
Grade 0 – no necrosis 
Grade 1- small foci of necrosis involving only less than of a 
high power field. 
Grade 2- necrosis involving less than one high power field. 
Grade 3-large confluent necrosis involving more than one 
high power field. 
• GRADING OF LOSS OF ARCHITECTURE: 
Grade 0- no sheeting architecture. 
Grade 1-   incipient loss of fascicular  arrangement of tumor 
cells. 
Grade 2 -    readily identifiable loss of pattern involving one 
to two high power fields. 
Grade 3 – large areas of solid pattern involving several high 
power fields. 
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ELECTRON MICROSCOPY: 
Diagnostic features include  
a)abundant intermediate (vimentin) filaments 
b)tight intercellular desmosomal junctions 
c)complex interdigitation of tumour cellular processes without basal 
lamina material. 
Secretory varisnt show single or even multiple epithelial like 
intarcellular lumina with single meningothelial cell.these cells exhibit 
short apical processes surrounding electron dense secretions. 
Microcystic meningiomas show intercellular electron lucent matrix 
enclosed by cytoplasmic processes which are bound  by desmosomes. 
IMMUNOHISTOCHEMISTRY: 
Majority of meningiomas typically stain for EMA with a 
characteristic membranous positivity or have diifuse cytoplasmic 
positivity.EMA positivity distinguish meningiomas from gliomas and 
schwannomas and hemangiopericytoma.Vimentin positivity is strong in 
all meningiomas. S100  is variably positive.It is useful in distinguishing 
meningiomas and schwannomas as schwannomas are strong S100 
positive. CEA(Carcinoembryonic antigen) is strongly positive in 
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secretory meningiomas. other markers which are expressed include 
progesterone receptors,Ki67.claudin is expressed in some of the cases. 
NCAM(Neural cell adhesion molecule) is strongly expressed in 
fibroblastic meningiomas. Types I,III,IV,V collagens and laminin are 
found in fibrous tumours.Endothelin 1 and endothelin receptors ET-Ar 
,ET-Br and PDGF,IGF are also expressed in meningiomas. 
RECURRENCE RATE : 
Meningioma 
Grade Incidence % 
Recurrance 
rate 
Grade I >90% 
Benign with less 
aggressiveness.<4mitoses/10hpf 
7-25% 
Grade II 4-7% 
Atypical with 4-19 mitotic 
activity/10hpf. Three or more of the 
following features such as increased 
cellularity, small cells with increased 
nucleus cytoplasmic ratio, prominent 
nucleoli, sheet like growth and focal 
or geographic necrosis. 
29-50% 
Grade III 1-3% 
Anaplastic with  histologic features 
of malignancy. They more 
commonly cause invasion. 
 
50-94% 
  
Predicting the recurrence rate and behavior of meningioma cannot 
be made solely on the basis of histopathological examination.7 to 20 % of 
benign grade 1 meningiomas are known for their recurrence.studying the 
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proliferation index provides a objective method of assessing tumour 
recurrences.(35) 
PROLIFERATION INDEX: 
 Ki-67 is an antigen expressed in proliferating cells throughout the 
cell cycle. MIB-1 is the antibody which targets the antigen Ki-67 and 
hence it is used in the measurement of  Proliferation index.Ki67 is 
expressed in the proliferative phase of the cycle(G1,S,G2,M phases of the 
cell cycle). Hence it is a reliable marker for assessing tumour growth and 
behavior.likewise MIB 1 labellling indices are used to indicate tumour 
proliferation rate and to plan the adjuvant therapy accordingly.(36) 
If there increased MIB-1 staining index then it represents higher 
histological grade aand increased risk for recurrence. Many studies have 
reported that for recurrent meningiomas there will be a high Proliferation 
Index compared to less aggressive ones.(37) 
Meningiomas having MIB-1 staining index of >4% then the 
propensity for recurrence of the meningioma is significantly higher. 
Various studies has shown that MIB-1 staining index is more in 
meningiomas with evidence of edema in MRI’s and in Males compared 
to females. According to Matsuno et al., 1996 in meningiomas with 
calcifications the MIB-1 staining index is comparatively lower. 
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LABELLING INDEX: 
 Labelling index represents the percentage of immunoreactive 
tumour cell nuclei. In determining labeling index tumour sampling may 
be the source of error because there will be histological heterogenicity 
with regional differences in cell proliferation. Because of this the labeling 
index should be analysed from the region of the tumour that is 
histologically most malignant. The Labelling index is higher for 
meningiomas in Neurofibromatosis patients depicting the more 
aggressive behavior of these meningiomas . The labelling index  of 
various grades of meningiomas are as following table.(38) 
Meningioma Grade Labelling Index 
Grade I 3% 
Grade II 8% 
Grade III 17% 
 
MOLECULAR GENETICS: 
 Merlin is a tumour suppressor which is located on the cell 
membranes and it regulates cell to cell contact and motility. This Merlin 
tumour suppressor is encoded in the NF2 gene which is located in 
chromosome 22. The absence merlin tumour suppressor results in 
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increased cell proliferation in meningioma cells. The most common gene 
alteration in meningioma is monosomy of chromosome 22. Inactivation 
of this merlin gene is responsible for occurance of 60% of sporadic 
meningiomas and for the rest of 40% of sporadic meningiomas the 
genetic background is not known. Deletions of short arm of chromosome 
22 (22q) is present in almost 100% of cases of  Neurofibromatosis 
patients. The frequency of gene alterations vary among different subtypes 
of benign meningiomas. 
 NF2 mutations occur in 70-80% of fibroblastic and transitional 
subtypes whereas only 25% of meningothelial subtype have NF2 
mutations. The frequency of NF2 mutations doesn’t vary in different 
histological grades and hence these mutations are presumed to occur in 
early part of tumorigenesis.  
 DAL-1 protein is also a transmembrane protein with tumour 
suppressor properties resembling merlin. The gene for DAL-1 protein is 
located in chromosome 18. In 76% of sporadic meningiomas the DAL-1 
expression is lost. Similar to merlin the loss of expression of DAL-1 
protein is similar among different histiological grades of a subtype 
indicating it as an early event in tumorigenesis. 
 Deletions in chromosome 1 has been associated with tumour 
progression. According to Bello et al., 1994 only 13-26% of benign 
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meningiomas represents 1p deletions where in anaplastic variant the 1p 
deletions is found in 70-100% signifying its role in tumour progression. 
Similarly deletions  in chromosome arm 14q has increasing frequency 
from low grade to high grade representing its role tumour progression. 
 Cytogenetic features of meningiomas differ among males and 
females. The frequency   of abnormalities in  Chromosome 22 and X are 
more common in females compared to males whereas the frequency of 
monosomy 14 is higher in males. Loss of chromosome X is found in 14% 
of female patients. 25% of male patients show chromosome Y nullisomy.  
Non-steroid hormone associated genetic factors which are encoded 
in the sex chromosomes may be involved in the development of 
meningioms. Differential classification of meningioma between males 
and females can be done based on eight genes which are differentially 
expressed among males and females(39) 
GENETIC ALTERATIONS: 
BENIGN: 
• NF2 gene mutations and chromosome 22 q loss 
• Ch Y loss 
• Ch 1p and 3 p loss 
• Ch 9q mutations 
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ATYPICAL/MALIGNANT: 
• Ch 1p loss 
• Ch 10 loss 
• Ch 14 q loss 
• TP53 mutations 
• CDKN2A/p16 gene deletions 
• Ch 6q,9q,18q loss 
• Ch 17q23 amplification 
• Ch 1 q,9q,12q,15q,17q,20q gains 
SEX HORMONE RECEPTORS IN MENINGIOMAS: 
 Progesterone is a steroid hormone which is involved in fertility of 
females, preparation of endometrium of uterus for the implantation of 
embryo and in maintainence of pregnancy. Hence it is named as the 
‘Steroid hormone of reproduction’.  
Besides the specific effects on endometrium the progesterone 
hormone also has some antiestrogenic and antiproliferative effects on 
other tissues. This lead to new interests in this hormone because of its 
effect in proliferation the progesterone hormone with its synthetic 
agonists and antagonists can be used in cancer therapy.  
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The action of progesterone is through the progesterone receptor 
and hence the study into the detailed function and regulation of these 
progesterone receptors will help in the management of tumours 
expressing these receptors. 
 Meningiomas are presumed to be hormone sensitive tumours 
because of the following facts 
1. Higher incidence of meningiomas in females than males. 
2. Meningioma and breast cancer association 
epidemiologically. 
3. The reduced aggravation of symptoms of meningiomas 
during pregnancy and luteal phase of menstrual cycle which 
are periods of relative progesterone excess indicating the 
effect of progesterone in these tumours. 
 But during pregnancy there may be increase in size of 
meningiomas which is due to cellular edema and not because of increased 
proliferation. 
 After the report of presence of ER in meningioma tissue various 
studies has been conducted based on this subject. Many studies have 
reported both ER and PR positive in meningiomas but some studies 
revealed ER negative and PR positive phenotype. This may be explained 
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by the methodological differences of assay of tumour tissue for ER 
receptors since many studies used single-point binding assays which is 
less reliable than the Immunohistiochemistric or enzyme-immuno 
analysis.  
Even though the presence estrogen receptors could be 
demonstrated in some meningiomas  it is present at a very low level 
compared to breast cancer in which there is more expression of ER 
receptors. The meningiomas shows ER negative and PR positive as 
predominant phenotype compared to Breast cancer which shows both ER 
and PR positive phenotype. 
PROGESTERONE RECEPTOR : 
The presence of  Estrogen and Progesterone receptor in 
meningiomas was  first described by  Donnel et al in 1979.In the intial 
days only receptor binding assays were only available to detect the 
Estrogen and Progesterone receptor which produced cumbersome results 
due to diiference in interpreting the results based on level of cytosolic 
receptor binding sites. However with the advent of monoclonal 
antibodies,detection of ER,PR is made easy, reliable and rapid using  
immunohistochemical techniques. 
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 The action of progesterone is mediated through progesterone 
receptors. The receptors for steroid hormones, retinoic acid and thyroid 
hormones along with orphan receptors form a super family of 
transcription factors. The characterization of specific functional domains 
in these proteins are conserved within a species and among family 
members. (40). 
The location of progesterone receptor is mainly in the nucleus 
which is maintained by a balance between a continuous active transport 
into the nucleus and diffusion into the cytoplasm of these receptors. The 
active transport of the progesterone receptor into the nucleus is done by 
Nuclear localization signal.  
The receptors contain two domains of which the DNA Binding 
Domain is highly conserved whereas the the carboxy-terminal which is 
the Ligand Binding Domain is less conserved. This Ligand Binding 
Domain contains a region called Activation function 2 (AF-2)  which is 
ligand dependant. The amino terminal of the receptor contains a region 
called Activation function 1(AF-1) which is ligand independent. 
  Both AF-1 and AF-2 act in a synergestic manner which is required 
for receptor function. Another domain region called AF-3 which is a 
strong autonomous activation domain function in a restricted cell and 
promoter context. 
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 The unliganded progesterone receptor is inactive and is attached 
with Heat shock proteins. When the ligand binds to the receptor it 
initiates a series of events as follows. 
1. Ligand binds to the progesterone receptor. 
2. The Heat shock proteins gets dissociated from the 
receptor. 
3. The tertiary structure of the receptor protein changes. 
4. Phosphorylation, dimerization and high affinity binding to 
progesterone responsive elements causes the activation of 
the receptor. 
5. The activated receptor interacts with Transcription 
machinery complex and initiates the transcription of 
progesterone responsive genes.  
 The activation of the transcription also requires some regulatory 
proteins called cofactors. Two isoforms of progesterone receptor exists 
which are PR-A and PR-B.  
The PR-B isoform has an additional stretch of 164 amino acids at 
the amino terminus which is called B Unique Sequence (BUS). The BUS 
region which encodes the AF-1 is specific to the PR-B isoform that plays 
a main role in specific target gene activation that cannot be activated by 
PR-A isoform.  
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The isoforms after binding with progesterone dimerize and interact 
with Progesterone responsive elements and also activate transcription 
which regulate PR target gene expression. When the isoforms are present 
in equimolar concentrations the dimerization can occur in three ways, 
A:A, B:B homodimers and A:B heterodimers each of which have 
different gene regulating properties. Thus in response to progesterone 
both PR-A and PR-B isoforms can regulate different physiological target 
genes since they have different transactivation capacities. In certain cell 
contexts the PR-A is capable of repressing PR-B transactivation and also 
Estrogen Receptor. 
 Thus PR-A isoform has the ability decrease the responsiveness of 
specific target genes by progesterone. Thus in treating benign breast 
diseases with progestins the differential expression of PR isoforms is 
important clinically. Thus in the treatment of meningiomas with 
progesterone derivatives the evaluation of the differential expression of  
isoforms of the progesterone receptors would be very helpful.   
 PR negative meningiomas are of more aggressive nature than 
progesterone receptor positive ones. Expression of progesterone receptors 
even in a small number of tumour cells is considered as a favourable 
prognostic factor as said by Hsu et al 1997.(37) 
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ESTROGEN RECEPTOR: 
 The expression of estrogen receptor is absent in normal meningial 
tissues. Estrogen receptor expression is found in approximately one third 
of meningiomas. It is also said that no relationship exists between 
estrogen and progesterone receptor expression in meningiomas. 
Estrogen receptor expression in meningiomas is associated with 
more aggressive behaviour..Meningiomas that have progressed from 
Benign to Atypical types had Estrogen receptor Expression of 30% 
compared to de novo atypical meningiomas in which estrogen receptor 
expression is 0%. (41)   
MANAGEMENT : 
SURGERY: 
As in cushings day ,surgery is the mainstay of treatment. Hence 
degree of resection is an important predictor of tumour recurrence. 
However complete resection is not possible in case of radiation induced 
meningioma as they are multiple and invasive lesions. 
Also the thin atrophic skin further limits the surgical option in 
previously irradiated patients presenting with radiation induced 
meningioma. 
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RADIOTHERAPY: 
This has a definitive role in reducing recurrences in post operative 
patients.various modalities are which are as follows 
Streotactic radiotherapy,intensity modulated 
radiotherapy,fractionated radiotherapy,and protons. 
HORMONES: 
Newer anti hormonal approaches have been developed based on 
promising results of breast cancer treatment.curently patients with 
progreesive disease following primary radiotherapy or post operative 
radiaton is treated with endocrine therapy. Mifepristone an oral anti-
progestational agent is tried. According to edwards et al mifepristone acts 
by inhibiting transcriptional activity of progesterone receptor by a 
complex mechanism at concentration much lower than progestins. 
Olson et al assessed the efficacy of mifepristone therapy in 
meningioma specimens which caused an inhibition of growth in vitro. 
These results encouraged the endocrine therapy as an alternative mode of 
therapy for unresectable  and recurrent meningiomas. 
Tamoxifen  is an oral ER modulator that binda to ER producing 
nuclear complexes that inhibits DNA synthesis and thereby inhibit 
estrogen (42). 
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MATERIALS AND METHODS 
STUDY DESIGN: 
          Cross sectional study 
PLACE OF STUDY: 
         Department of Pathology, Coimbatore Medical College Hospital, 
Coimbatore 
STUDY PERIOD: 
     July 2013-July 2014 
INCLUSION CRITERIA: 
 1.All meningioma specimens received in the Department of pathology. 
2.Well  fixed adequate tissue 
 EXCLUSION CRITERIA: 
     1.Inadequate tissue for multiple sectioning 
     2.Ill fixed specimen 
Sections were cut at four micron thickness on to a coated slides 
which are then incubated at 58 degrees overnight.Initial sections were 
stained with hematoxylin and eosin stain. 
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HEMATOXYLIN & EOSIN STAINING METHOD: 
REAGENTS USED: 
1.Hematoxylin solution-Erhlich’s hematoxylin 
2.EosinY 1% solution 
3.Acid alcohol 1% solution 
PROCEDURE: 
1.Deparaffinize sections in xylene by immersing for 30 seconds. 
2.place the sections in Isopropyl alcohol for 15 minutes 
3.Wash in running tap water 
4.stain in Erhlich’s hematoxylin for 10 to 15 minutes 
5. wash in running tap water 
6.Differentiation is done with 1% acid alcohol-two to three dips 
7.blueing is carried out for 10 minutes. 
8.Counterstain with eosin 1% solution-3 to 4 dips 
9.Running tap water wash 
10.Air dry 
11.Mount with DPX 
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The sections are studied based on histomorphological features and a 
diagnosis is obtained. 
 IMMUNOHISTOCHEMISTRY: 
METHODS: 
Two step indirect technique 
PRINCIPLES OF IMMUNOHISTOCHEMISTRY: 
This technique relies on detection of antigens expressed the cells 
and tissues with the two step process 
 1.Primary antibody is bound to antigens using specific epitopes 
2.Calorimetric reaction that follows detects the antigen antibody binding. 
REAGENTS: 
1.Peroxide block: Hydrogen peroxide 3 % in water 
2.Power block: This is an effective protein blocking reagent.It contains 
casein and properity additives with 15 mM sodium azide in PBS 
3.Chromogen: DAB- 3 3’ diaminobenzidine 
4.Liquid DAB substrate: Tris buffer containing stabilizers and peroxides. 
5.Super Enhancer 
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6.Mayers hematoxylin is used to counterstain. 
7.Buffer solutions 
TRIS BUFFER(pH 7.6) 
TRIS buffer salt:0.605grams 
Nacl                      :8 grams 
Distilled water      :1 litre 
1N HCL                :3 ml 
CITRATE BUFFER(pH 6.0) 
Trisodium citrate: 2.94 grams 
Distilled water :1 litre 
1N HCL:5 ml 
TRIS EDTA:(pH 9.0) 
TRIS Buffer salt:6.05 grams 
Disodium EDTA:O.744 grams 
Distilled water: 1 liter 
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PROCEDURE: 
1.Deparaffinise sections in xylene  for 30 minutes 
2.keep in absolute alcohol for 10 minutes 
3.wash in running tap water for 10 minutes 
4.Dip in distilled water for 5 minutes 
5.Antigen retrieval done by placing slides in microwave with appropriate 
buffer solutions. 
6.Cool the sections to room temperature 
7.Rinse the sections in distilled water 
8.TBS  buffer wash-5 minutes  2 changes 
9.Peroxide block for 10 minutes 
10.TBS Buffer wash – 5 minutes 2 changes 
11.power block -10 minutes 
12.Primary antibody is used to cover the sections(supplied by 
DAKOCYTOMATION) 
13.TBS Buffer wash-5 minutes 2 changes 
14.Cover the sections with Super Enhancer for 30 minutes 
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15.TBS Buffer wash -5 minutes 2 changes 
16.Apply poly HRP reagent for 30 minutes 
17.TBS Buffer wash -5 minutes 2 changes 
18.Trat with DAB chromogen and substrate buffer for 5 to 8 minutes 
19.TBS Buffer wash 5 minutes 2 changes 
20.Wash the slides in running tap water for 5 minutes  
21.Counterstain in Mayers hematoxylin -1 minute 
22.Tap water wash for 5 minutes 
23.Air dry, mount in DPX. 
Positive control  for progesterone and estrogen receptor includes 
breast cancer slides that is ER,PR immunoreactive. Positive control for 
Ki67 includes lymph node that is immunoreactive for Ki67. Negative 
control was also run each time   
Immunohistochemical evaluation: 
The entire sections in a slide is examined under high power 
objective for the presence of positive immunoreactivity. Tumour cells are 
read positive if there is golden brown nuclear staining of the neoplastic 
cells. Semiquantitative scoring was carried out. 
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Grading of intensity staining: 
0-absent 
1-weak 
2-moderate 
3-strong 
Percentage of positive tumour cells: 
0-absence of positive tumour nuclei 
1-10% of cells are positive 
2-10-50% of cells are positive 
3-51-80% of positive tumour cell nuclei 
4->80% are positive tumour cell nuclei 
Progesterone receptor was read as positive if >10% of cells shows 
strong immunostaining or >50% of cells show moderate staining.  For Ki 
67 labelling index each slide was examined under high power and hot 
spot was selected. Hot spot is an area with highest immunostained nuclei. 
1000 tumour cell nuclei was counted and the  labelling index was 
expressed as percentage  of positive cells. Caution should be expressed 
while interpreting Ki67 positivity as any proliferating cell such as 


lymphocytes can be positive.Hence hot spot should always be selected 
after meticulous comparision with routine H&E sections. 
Data: 
Tumour was subtyped according to new WHO classification using 
H&E sections. Patient age, gender, progesterone receptor , estrogen 
receptor status,Ki67 was determined and expressed. 
Statistical analysis: 
SPSS software version 15 was used for analysis and the variables 
were expressed as percentage of number (percentage %).Chi square tests  
was employed for statistical comparisons. P value <0.05 was considered 
statistically significant. 
. 
  
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OBSERVATION AND RESULTS 
The present study is a prospective study conducted in the 
Department of  Pathology,Coimbatore Medical college Hospital. A total 
of 30 cases of meningioma specimens received over the period  of July 
2013 to July 2014 were studied. 
Ethical clearance was obtained from Ethics committee of 
Coimbatore  Medical College and Hospital,Coimbatore. 
Histomorphological and immunohistochemical pattern of 
expression was studied , analysed and compared with the literature. 
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TABLE 1 
AGE WISE DISTRIBUTION OF MENINGIOMAS(n=30) 
AGE CASES 
<40 YEARS 14(46.6%) 
>40 YEARS 16(53.3%) 
 
In the present study out of total 30 cases, 14 cases were <40 years 
which constitutes around 46.6% and 16 cases were in age group >40 
years which constituted around 53.3%.Patients age group ranges from 27-
75 years with mean age of  45 .7 +/- 13.1 years .  
AGE DISTRIBUTION OF MENINGIOMAS 
 
As noted from above Pie chart , in the current study ,age group >40 
years were higher with 53.3% than age group <40 years which was on
46.6% .Mean age of patients in the present study was 45 .7 +/
. 
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SEXWISE
TOTAL CASES: 30
MALES: 8 CASES
FEMALES: 22 CASES
 
 
In the present study females constituted arou
outnumbering  males which were 8 cases(27%)
 FEMALE:MALE RATIO: 2.7:1
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                                              TABLE 2 
ANATOMICAL SITE WISE DISTRIBUTION OF MENINGIOMAS 
 
LOCATION CASES 
Supratentorial 19(64%) 
Infratentorial  4(13%) 
Spinal 7(23%) 
 
Among 30 cases studied ,19 cases were Supratentorial in location 
and 7 cases were Spinal  (23%),and only 4 cases were Infratentorial in 
location in the present study. 
 
 
 
 
 
 
 
 
 
 
ANATOMICAL SITE WISE DISTRIBUTION OF 
 
 
 
In the current study ,as depicted in the above Exploded Pie chart 
supratentorial location was the most common  among  other tumours 
followed by Spinal tumours constituting around 23% and Infratentorial 
tumours were least in location 
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TABLE 3 
 
INCIDENCE OF VARIOUS SUBTYPES 
 
SUBTYPE PERCENTAGE IN THE STUDY 
Meningothelial 23% 
Transitional 50% 
Fibrous 17% 
Psammomatous 7% 
Angiomatous 3% 
 
In the present study among grade I tumours, which has 13 subtypes 
only five subtypes was observed commonly. Among the five subtypes, 
Transitional was the most commonly observed subtype constituting about 
50 %,followed by Meningothelial which was around 23%,fibrous subtype 
(17%),Psammomatous type(7%),Angiomatous subtype. 
 
 
 
 
 
 
INCIDENCE OF VARIOUS SUBTYPES
 
As depicted in the above Pie chart, Transitional was most common 
subtype among others followed by other subtypes in decreasing order   
Meningothelial, Fibrous, Psammomatous, Angiomatous.


CHART 4 
 
 
 
 
 
 
 
 
 
"#
$
%

&"
HORMONAL
 
HORMONAL RECEPTOR POSITIVITY:
TOTAL CASES:30
PROGESTERONE POSITIVE CASES: 19(63.3%)
PROGESTERONE  NEGATIVE CASES:11(37%)
ESTROGEN RECEPTOR POSTIVITY:0(0%)
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TABLE 4 
AGE WISE DISTRIBUTION OF PROGESTERONE RECEPTOR 
EXPRESSION 
AGE PR+VE PR –VE 
<40 YRS 11 (79%) 3 (21%) 
>40YRS 8 (50%) 8 (50%) 
 
In the current study out of 30 cases, 14 cases were seen in age 
group of < 40 yrs of which 11(79%) were PR positive and 3 (21%) were 
PR negative. Whereas out of the 16 cases which were > 40 yrs age group 
8 (50%) were positive and 8(50%)  were negative.  These results were 
analysed using chi-square analysis and found to be statistically 
insignificant .(p=0.074) 
 
 
 
 
 
 
 
 
 
AGE WISE DISTRIBUTION OF PROGESTERONE RECEPTOR 
 
 
In this clustered column diagram it is seen that PR positivity was 
higher in age group <40 years with 11(79%) out of 14 cases showing PR 
positivity than in age group >
and PR negative cases
analysis and found to be statistically insignificant.(p=0.074)
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. These results were analysed using chi
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TABLE 5 
SEX WISE DISTRIBUTION OF  PROGESTERONE RECEPTOR 
EXPRESSION 
SEX PR ‘+’ve (n) 
PR ‘-‘ ve 
(n) 
Male 4(50%) 4(50%) 
Female 15(68%) 7(32%) 
 
In the present study out of 22 females,15 cases (68%)were PR 
positive and 7 cases were PR negative. Whereas among 8 males PR 
positive and PR negative were 4 cases each that is 50% each. Chi-square 
analysis showed a p value of 0.03 which is statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
SEX WISEDISTRIBUTION OF 
 
 
In the present study as seen from this bar chart PR positivity was 
significantly higher in females about 68%
positive and negative cases were 50 % each.
statistically significant.
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 than in males in which both PR 
 These observations were
(p<0.03) 
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TABLE 6 
PR STATUS IN MENINGIOMA SUBTYPES 
 
SUBTYPES PR +ve PR -ve 
Meningothelial 43% 57% 
Transitional 73% 27% 
Fibrous 60% 40% 
Psammatous 50% 50% 
Angiomatous 100% 0% 
 
 
As seen in the above table , PR positivity was  100 % in 
Angiomatous subtype followed by Transitional  subtype showing 73% 
PR positive cases ,followed by Fibrous exhibiting 60% PR positivity. 
Psammomatous showed 50 % of  PR positive and PR negative cases.PR 
positivity was least in Meningothelial subtype(43%).These  results were 
statistically insignificant. .(p=15.7) 
 
 
 
 
PROGESTERONE RECEPTOR STA
 
 
In the present study as seen from the Bar chart, Angiomatous 
subtype showed 100% PR positivity and least PR positive subtype was 
Meningothelial subtype with only 43% cases showing Immunoreactivity 
for Progesterone receptor
insignificant.(p=15.7)
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TABLE 7 
PROGESTERONE RECEPTOR EXPRESSION IN VARIOUS 
LOCATIONS 
 
LOCATION PR +ve PR -ve 
Supratentorial 13(68%) 6(32%) 
Infratentorial 2(50%) 2(50%) 
Spinal 4(57%) 3(43%) 
 
From the above table  PR positivity was higher in 
supratentorial tumours with 13 case(68%)s out of 19 cases, 
followed by spinal tumours with 4 out of 7 cases showed PR 
positivity. Infratentorial tumours showed  equal PR positive and 
negative cases with 50 % each. Chi square analysis showed a 
statistically insignificant result .(p=0.67) 
 
 
 
  
 
 
PROGESTERONE RECEPTOR EXPRESSION IN VARIOUS 
 
 
As depicted in the above Clustered cylinder column,
immunoreactivity was expressed by 
followed by spinal tumours with 57%.Infratentorial tumours showed 
equal PR positivity and PR negativity with 50% each.
analysis showed a stat
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CHART 9 
LOCATIONS 
68% of supratentorial tumours
istically insignificant result. 
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TABLE 8 
INCIDENCE OF RECURRENCE 
 
CASES NUMBER 
Non recurrent 23 
Recurrent 7 
Total 30 
 
In the present study total of 30 meningioma  cases were studied, all 
of which were grade I tumours .Among grade 1 tumours ,recurrence was 
seen in 7 cases(23%) and 23 cases(77%) were non recurrent cases. 
 
 
 
 
 
 
 
 
 
 
 
INCIDENCE OF RECURRENCE
 
 
As seen from the above Exploded 3
recurrent cases were around 77 % that is 23 cases, and recurrent cases 
were around 23% that is 7 cases.
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TABLE 9 
AGE DISTRIBUTION OF RECURRENT TUMOURS 
 
AGE  NON RECURRENT RECURRENT 
<40 YRS 12(86%) 2(14%) 
>40 YRS 11(69%) 5(31%) 
 
Out of total 30 cases, 14 cases were <40 years, out of 14 cases  
only   2 cases showed recurrent tumour. Whereas out of 16 cases in age 
group >40 years,5 cases that is 31% showed recurrence. However 
recurrence was insignificantly related to age.(p=1.02) 
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As noted in the above 3
recurrence was noted higher in age group 
16 cases showed recurrence, than in age group <40 years where only 2 
out of 14 cases showed recurrence.
insignificantly related to age.(p=1.02)
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TABLE 10 
RECURRENT TUMOURS AND SEX DISTRIBUTION 
Sex Primary Recurrent 
Male 6(75%) 2(25%) 
Female 17(77%) 5(23%) 
 
In the present study, recurrent tumours were analysed with sex 
distribution . As noted from above table, recurrence was higher in males 
in which out of 8 males , 2 cases that is 25% showed recurrence whereas 
out of 22 cases of females, only 5 cases showed recurrence which 
constituted around 23%.Using chi-square test p value is 0.01 ,which is 
statistically significant 
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As observed in the above stacked cylinder column chart,
recurrence was slightly 
showed recurrence   
chi-square test ,  p valu
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TABLE 11 
PROGESTERONE   RECEPTOR   STATUS IN NON 
RECURRENT  VS RECURRENT TUMOURS 
CASES PR + ve PR – ve 
Non recurrent 18(78%) 5(22%) 
Recurrent 1(14%) 6(86%) 
 
As noted from the above table, Progesterone receptor 
immunoreactivity was analysed with non recurrent and recurrent 
tumours.PR positivity was expressed in higher percentage in non 
recurrent tumours than that of  recurrent tumours. Out of total 23 primary 
cases, almost 18 cases (78%)showed PR positive immunoreactivity, 
Whereas among 7 recurrent cases only one case showed positive PR  
immunoreactivity. These results were statistically significant by chi-
square analysis. (p=0.03) 
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In the current study,
immunoreactivity was significantly higher
showed  PR positivity 
significant  and only 
These results were statistically significant by chi
(p=0.03) 
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 out of total 30 cases,
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-square analysis.
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TABLE 12 
Ki67 EXPRESSION IN MENINGIOMAS  
 
MARKER CASES 
Ki67 +ve  13(43%) 
Ki67 -ve  17(57%) 
 
In the current study,Ki67 a proliferative marker, is expressed in 13 
out of 30 cases and the remaining  17 cases (57%) were negative. It is 
clear from the above table that Ki67 negative cases were in higher 
percentage in grade I meningioma than Ki67 positive cases. 
 
 
 
 
 
 
 
 
 
 
Ki67 EXPRESSION IN MENINGIOMAS
 
 
As shown in the above pie chart,
significantly higher than Ki67 positive cases. Out of total 30 cases 
observed in the current study, 17 cases did not exhibit Ki67 
immunoreactivity and  remaining 13 cases was Ki67 positive.
 
 
 
		
CHART 14 
 Ki67 negative 
 
 
.)*

.+*


  
 
cases were 
 
	


TABLE 13 
Ki67 STATUS AND RECURRENCE 
   
CASES Ki67 +ve Ki67 –ve % 
Non recurrent 6(26%) 17(74)%) 
Recurrent 7(100%) 0(0%) 
 
In the present study, Ki67 immunoreactivity was analysed in non 
recurrent and recurrent cases . All the 7 recurrent cases were Ki67 
positive. Whereas only 6 cases out of 23 of  non recurrent cases were 
Ki67 positive. These results were statistically significant by chi square 
analysis. (p value <0.001) 
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As depicted in the above clustered cylinder column chart,
that all the 7 recurrent cases showed Ki67 positivity which was 
statistically significant.
cases showed Ki67 positivity.
square test which is statistically significant
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 Whereas out of 23 non recurrent cases only 6 
 These results were analysed using Chi
 . (p value <0.001)
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TABLE 14 
CORRELATION OF PROGESTERONE RECEPTOR AND Ki67 
EXPRESSION 
 
MARKER Ki67 +ve Ki67 –ve 
PR +ve  4(21%) 15(79%) 
PR –ve  9(82%) 2(18%) 
 
In the present study, PR immunoreactivity was compared with 
Ki67 expression. From the above table an inverse relationship was 
observed between PR and Ki67 expression. That is out of 19 PR positive 
cases  ,almost  15 cases were Ki67 negative whereas out of 11 PR 
negative cases , Ki67 was positive in 9 cases. Chi-square analysis showed 
a statistically significant result. p<0.003 
 
 
 
 
 
 
 
CORRELATION OF PROGESTERONE RECEPTOR AND Ki67 
 
From the above clustered cylinder column chart, an inverse  
relationship was observed
of 19 PR positive cases ,
out of 11 PR negative cases , Ki67 was positive in 9 cases. Chi
analysis showed a statistically significant result
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DISCUSSION 
 
Meningiomas constitute the single largest group of tumour arising 
from the meningothelial cells. It can range from benign meningioma 
(WHO grade I) to atypical and anaplastic meningioma (WHO grade II 
and grade III) respectively. Meningioma constitute about 13-26% of 
primary intracranial tumours. The annual incidence rate of meningioma is 
about 6 per 100000 population. Of these benign meningiomas constitute 
the majority of cases followed by atypical and anaplastic meningioma. 
Yet benign grade I meningiomas have an increased tendency to recur.(38) 
Eventhough tumour grade and subtype are strong prognostic factors 
,benign biologically aggressive meningiomas cannot be identified by 
routine histology alone. Hence the need for identification of newer 
prognostic indicators arises ,to predict the clinical behaviour. Various 
literature have shown that detection of progesterone receptor and 
proliferative index Ki67 might predict the clinical behaviour of 
meningioma and patient survival. 
 In the present study three factors that is progesterone receptor, 
Estrogen receptor expression, proliferation indices were studied in the 
meningioma specimens and their possible correlation were analysed 
demographically, histomorphologically and by immunohistochemistry. 
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Thirty cases with meningioma were included in the study. The age 
of patients ranges from 27 – 75 years. Mean age was   45 .7 +/- 13.1 
years. (TABLE 1).This is in accordance  with the  results by El-Badawy 
et al (2013) in which mean age was 46.7 years. (43)Similar studies 
conducted by Ashraf Fakhrjou et al (2012),and in Chennai by Shalinee 
Rao et al(2009)showed mean age was 52.9 years.(44),(45) Also a study by   
Roser et al(2004) in which 505 meningiomas specimens was examined , 
the mean age of PR positivity was 55.4 years .(46) 
Out of 30 cases studied , females were 22 in number outnumbering 
males who were 8 in number(.i.e)Females constituted around 73.3% and 
males  were 27%.The female: male ratio is 2.7:1.(TABLE 2).This is 
similar to the study by Ashraf Fakhrjou et al (2012) in which out of 50 
cases, Females were 76.5%(n=26),males  were 23.5 %(n=8)(44). Al-
Nuaimy et a (2012) studied 50 meningioma cases in which females 
(n=34) outnumbered males (n=16).(47) Shalinee Rao et al (2009) similarly 
showed a increased female: male ratio with 1.4:1(45).Nasirin Shayanfar et 
al (2009) studied 78 cases in which F:M ratio was 2.5:1(48).Similar  
studies by Taghipur et al (2007) showed out of 51 cases ,21cases were 
females with males constituting only 20 cases(49) and study by Sndan 
Milenkovie et al (2004)  also showed a female preponderance .(50) 
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Incidence of various subtypes is as follows. 
 
 
Transitional 
(%) 
Meningothelial 
(%) 
Fibrous 
(%) 
Angio-
matous 
(%) 
Psammo-
matous 
(%) 
Current 
study 
50 23 17 13 7 
Milenkovie 
et al., 2004 
10 26.6 40 6.6 6.6 
Shayanfar et 
al., 2009 
36 40 24 - - 
 
The study includes the following subtypes of meningiomas, 
Transitional type, Meningothelial type, Fibrous type, Angiomatous and 
Psammomatous subtypes. Of these transitional meningioma found to be 
the most common subtype ,constitutes about 50%,which is followed by 
meningothelial subtype which constitutes around 23%.The other subtypes 
were fibrous ,angiomatous, and psammomatous which constitutes around 
17%,13%and 7% respectively. (TABLE 3) A study by Shayanfar et al., 
2009 showed Meningothelial subtype to be the most common of all 
constituting around 40% followed  by transitional and fibrous constituting 
about 36% and 24 % respectively. (48)These values in the present study 
were approximately same as in these studies. A study by Al-Nuaimy et al 
(2009) also showed a similar result with 57% of meningothelial cases.(47) 
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Out of  total thirty cases studied nineteen cases were PR positive 
and eleven cases were PR negative  which constitutes 63% and 37% 
respectively. None of the thirty cases showed immunoreactivity to 
Estrogen  receptor .(CHART 5). Similarly the expression of PR in various 
other studies are as follows. According to Al-Nuaimy et al., 2012  PR 
positivity was present in 72% of cases with 28% negative. (47) In a study 
by Shayanfar et al., 2009 the PR positivity was 96.8% (48), in another 
study by Taghipur  et al., 2009 the PR positivity was noted in 68.6% of 
cases(49) and a study by Milenkovie et al., 2004 out of 30 cases  PR 
positivity was present in 57% of cases.(50) In all above studies ER was not 
expressed in any of the case. Thus comparing all the above studies there 
is a consistent expression of PR positivity of more than 50%, and ER was 
0% Thus our study correlates well with all the above studies. 
PR positivity was analysed with the age of the patients. Of total 30 
cases , patients with age less than 40 years  were 14 in number which 
constituted around 46.6% and patients with age equal to or more than 40 
years, were 16 in number which  constituted about 53.3%.Fourteen cases 
with age less than 40 years, PR positivity was observed in 11 
cases(78.5%) and 3 cases(50%) were PR negative . Out of 16 cases with 
age  equal to or more than 40 years PR positive and negative were equal. 
In short PR positivity was observed  higher in patients  of less than 40 
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years (TABLE 4).These  results were analysed by chi-square analysis and 
p value was 0.074.Hence PR was insignificantly related to age. However  
a study by Al-Nuaimy et al ,in 2012, PR was positive in age group of 41-
50 years which is slightly higher in age compared to the present 
study(47).Also  Roser et al (2004) showed mean age of PR positivity to be 
55.4 years for females and 51.5 years for males.(46) 
              PR positivity was analysed with sex of the patients. Of the total 
30 cases, 22 were females and 8 were males. Out of  22 females,  PR 
positive immunoreactivity was  observed in 15 cases which constituted 
around 68%  and the remaining 7 cases were PR negative which is 
37%.Of the 8 males studied PR positive and negative cases were equal 
,50% each.(TABLE 5)In a similar study by Al-Nuaimy et al.,2012 PR 
was expressed in 72% of females and 20% of males.(47) Another study by 
Taghipour et al., 2007, 80% of female cases showed PR positivity 
similarly 67.5% of females cases  showed PR positivity  (Veherjein et 
al.,2001).(49) 
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Percentage of  PR positivity in various subtypes mentioned below: 
(TABLE 6) 
 
Mening-
othelial Transitional Fibrous 
Psammo-
matous 
Angio-
matous 
Current study 43% 73% 60% 50% 100% 
El-Badawy et 
al., 2013 
100% 50% 33.3% - - 
Al-Nuaimy et 
al., 2012 
83% 75% 100% - 66.6% 
Omulecka et 
al., 2006 
100% 95% 46% - - 
Roser et al., 
2004 
64.6% 50% 31% 60% 66.6% 
 
Grade I meningioma subtypes observed in the present study were 
Transitional, Meningothelial, Fibrous,Angiomatous,Psammomatous. PR 
status was analysed with the various subtypes observed in our study. PR 
positivity was expressed by 100% of angiomatous subtype followed by 
Transitional type which showed 73% PR positivity .The other subtypes 
with PR positivity in decreasing order is as follows-Fibrous, 
Psammomatous, Meningothelial with 60 %,50%,43% respectively. These 
results were analysed using Chi-square test which showed a p value of 
15.7.Hence PR expression was insignificantly related to meningioma 



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subtypes. Various other studies show a differing results.A study El-
Badawy et al., 2013 in which meningothelial showed 100 % PR 
expression followed by Transitional 50%, fibrous 33.3% (43).Another 
study by Al-Nuaimy et al 2012,showed a contrasting result in which  PR 
positivity was 100% in fibrous subtype followed by the below mentioned 
subtypes in decreasing order –meningothelial 83%, Transitional 
75%,Angiomatous type 66.6%.Roser et al in 2004 showed angiomatous 
subtype with maximum PR expression constituting  about 66.6% 
followed by meningothelial 64.6%,psammomatous 60 %,transitional 50% 
and fibrous 31.1% (47).A study by Omulecka et al 2004,showed a 100 % 
PR positivity in Meningothelial subtype followed by transitional 
95%,fibrous 46 % (51).These differing results could be explained by the 
various stem cell factors involved in the Progesterone receptor expression 
in meningiomas. 
Correlation of site of occurance and PR positivity (TABLE 7 ) 
In the present study, out of 30 cases ,19 cases were supratentorial 
in location,7 cases were spinal,4  were infratentorial in location. Of the 
total 19 supratentorial cases, positive PR  immunoreactivity was observed 
in 13 cases which consititued about 68.42%.Of the 7 spinal cases 4 were 
PR positive which were around 57%. Infratentorial tumours showed equal 
PR positive and PR negative cases with 50% in each group.Thus PR 

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positivity was higher in supratentorial tumours than in spinal  and 
infratentorial tumours.However Chi-square analysis showed a statistically 
insignificant relation between PR expression and location of tumour. 
(p>0.05) .These results were similar to other study by Milenkovie et al 
(2004) in which  no statistically significant correlation was obtained 
between PR expression and location of the tumour. (51) 
From the thirty meningioma cases included in the study, incidence 
of recurrence was analysed. Criteria for recurrence is, Known case of 
meningioma, (i.e) previously diagnosed and proved as meningioma by 
histopathology, now again presenting with clinical, and radiological signs 
of meningioma and  proved as meningioma by histopathology , was taken 
as recurrence. Of the 30 cases ,recurrence was seen in 7 cases and non 
recurrent cases were 23 in number.(i.e)recurrent cases  constituted around 
23% and recurrent cases was77% (TABLE 8).These results were in 
accordance with a study by El-Badawy et al., 2013 ,in which out of  30 
meningioma cases, non recurrent and recurrent cases were equal  
constituting 50 % each, (43) and also a study by Al-Nuaimy et al 
(2012),where a total of 50 cases were studied in which non-recurrent 
cases were around 86% and recurrent cases constituted around 14%, (47) 
and also a study by Vranic 2010,where out of 54 cases studied, non 

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recurrent cases were 35 in number and recurrent cases were 19 in 
number.(35) 
In the present study, age distribution of recurrent tumours were 
analysed. Cases <40 years who presented with recurrence were around 
14.2% (n=2)and patients >40 years  with recurrence were 31.2%(n=5) 
(TABLE 8) 
Similar results were seen in studies by El-Badawy et al  (2013),Al-
Nuiamy et al (2012) no correlation was observed between recurrence and 
age of the patients.(43,47) 
In the present study, sex wise distribution of recurrent tumours 
were analysed.2 out of 8 males show recurrence which constitutes 25%, 
in contrast only 5 out of 22 females (23%) show recurrence (TABLE 
10).These results were analysed using chi-square analysis which is 
statistically significant with p value of 0.01.This is  similar to study by 
El-Badawy et al (2013)(43) which showed recurrence to be more common 
in males than females,and a study by Al-Nuaimy et al (2012)(47) in which 
recurrence was higher in males. 
PR positivity in non recurrent and recurrent tumours:(TABLE 11) 
In the current study, PR positive immunoreactivity was observed in 
78% of non recurrent cases and 14% cases of recurrent cases. The results 
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
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were analysed using chi-square analysis which is statistically 
significant.(p=0.03) Our results were similar to results obtained in study 
by Al-Nuaimy et al (2012) in which PR positivity was observed as 72% 
and 42% in non-recurrent and recurrent tumours respectively (47).Also a 
study by Roser et al (2004) showed a higher PR positivity in primary or 
non recurrent tumours(53.5%)than in recurrent tumours.(46) 
Ki 67 status in our current study was 43 % positive   (TABLE 12) 
which is similar to a study by Ashraf  Faharjon et al., 2012 , Ki 67 
positivity of 38%.(44) 
On comparing the Ki 67 positivity among primary and recurrent 
meningiomas, it was 100% positive in recurrent tumours compared to 
only 26% of positivity in primary meningiomas. (TABLE 13),which is in 
accordance with  a study by Uranic et al., 2010 and Shalinee Rao et al., 
2009,  Ki 67 positivity was higher in recurrent tumours(.45) and  also the 
study by El- Badawy et al., 2013 ,where the mean Ki67 positivity was 
more in  recurrant tumours.(43) 
In our current study the relationship of  Ki 67 positivity and PR 
status was inversely proportional i.e  Ki 67 positivity was present in only 
4(21%)  PR positive cases with Ki 67 negative in 15(79%)  in a total of 
19 PR positive cases in our study(table 14). This result correlates well 
with other studies  which are as follows.   

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In a study byEl- Badawy et al (2013) mean Ki67 positivity in PR 
negative tumours was 10.31% whereas in PR positive cases, mean Ki67 
positivity was only 3.56 (43).Another study by Al-Nuaimy et al (2012) 
showed  mean Ki67 positivity in PR positive cases as 1.6%  and 5.8% in 
PR negative cases(47). Mauiri et al (2009) showed high Ki67 positivity in 
PR negative cases were highly predictive of recurrence. (52) 
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SUMMARY & CONCLUSION 
                   Meningiomas are categorised into three grades according to 
WHO classification. In general WHO grade I tumours behave in a benign 
fashion. (53).However a small subset of tumours appear  morphologically  
benign   and biologically aggressive. Detection of these subset of  
meningiomas is not in routine practice. Thus the study of  Progesterone 
receptor, Estrogen receptor and Ki67 markers were used as an adjuvant 
approach in the identification of  these histologically “on the fence” 
tumours.(54)          
               Thirty cases of meningioma were included in the study, all of 
which were Grade I tumours. Progesterone receptor positivity is  seen  in 
about 63.3% of cases, with none of the 30 cases showing 
immunoreactivity to estrogen receptor.PR expression was higher in 
females(68%) in comparing with the males. Age, location of tumour and 
meningioma subtypes had no correlation with PR.(55) The recurrence rate 
was found to be higher in males (25%). Progesterone expression was 
higher in Non recurrent tumours (78%). In recurrent tumours, PR 
expression was decreased (14%) but in contrast  Ki67 expression was 
100% .  There is an inverse relationship  between  Ki67  and Progesterone 
receptor expression.(56) This  suggests  the  role of  Ki67 in the prediction 
of  recurrence.(57)  Age, Location of tumour and the meningioma subtypes 

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has no role in predicting the recurrence. Although meningiomas  express 
progesterone receptor, it is independant of  Estrogen receptor, unlike the 
other hormone dependant tumours like breast and uterus(58).Expression of 
Progesterone receptor  is associated with lesser recurrence and better 
prognosis. These observations re emphasize the need to identify 
morphologically benign , biologically aggressive meningiomas which can 
be accomplished with the help of immunohistochemistry using 
Progesterone receptor and Proliferation index. Progeterone receptor can 
be used along with other histological parameters for prognostication of 
meningiomas(59,60) 
In the grading of meningiomas , histopathological examination 
alone is not sufficient, ancillary tests with Progesterone receptor and 
proliferative marker should be included for prognostication of 
meningiomas. 
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ANNEXURE II 
PROFORMA 
COIMBATORE MEDICAL COLLEGE 
DEPARTMENT OF PATHOLOGY 
COIMBATORE 
 
Particulars of the patient: 
Name  :                                IP/OP NUMBER: 
Age:                                     Ward number: 
Sex:                                        occupation:        
Address: 
Presenting complaints: 
Headache 
Seizures 
New neurological deficit 
Proptosis 
 
Family history: 
Malignancy +/- 
Personal history: 
Radiation exposure 
GENERAL PHYSICAL EXAMINATION: 
Built:                                                       Febrile : 
Nourishment :                                        Pallor: 
Conscious :                                             Jaundice: 
Weight :                                                 Cyanosis: 
Pulse rate:                                               Clubbing: 
Respiratory rate :                                   Lymphadenopathy: 
SYSTEMIC EXAMINATION: 
RS:                                                P/A: 
CVS:                                              CNS: 
CLINICAL DIAGNOSIS: 
RADIOLOGICAL FINDINGS: 
X RAY: 
CT: 
MRI: 
MICROSCOPIC FINDINGS: 
Histopathological diagnosis: 
Immunohistochemistry: 
FINAL DIAGNOSIS: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

ANNEXURE III 
ABBREVIATIONS 
ER-ESTROGEN RECEPTOR 
PR-PROGESTERONE RECEPTOR 
BI-BRAIN INVASION 
TP-TEMPERO PARIETAL 
PO-POSTERO OCCIPITAL 
MCF-MIDDLE CRANIAL FOSSA 
FP-FRONTO PARIETAL 
CP-CEREBELLO PONTINE ANGLE 
RT-RIGHT 
LT-LEFT 
NEG-NEGATIVE 
POS-POSITIVE 
  
